- Home
- UONEK vs SCYX Comparison
UONEK vs SCYX Comparison
Compare UONEK & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UONEK
- SCYX
- Stock Information
- Founded
- UONEK 1980
- SCYX 1999
- Country
- UONEK United States
- SCYX United States
- Employees
- UONEK N/A
- SCYX N/A
- Industry
- UONEK Broadcasting
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- UONEK Consumer Discretionary
- SCYX Health Care
- Exchange
- UONEK Nasdaq
- SCYX Nasdaq
- Market Cap
- UONEK 31.6M
- SCYX 28.5M
- IPO Year
- UONEK N/A
- SCYX 2014
- Fundamental
- Price
- UONEK $0.65
- SCYX $0.73
- Analyst Decision
- UONEK
- SCYX
- Analyst Count
- UONEK 0
- SCYX 0
- Target Price
- UONEK N/A
- SCYX N/A
- AVG Volume (30 Days)
- UONEK 12.9K
- SCYX 114.5K
- Earning Date
- UONEK 08-07-2025
- SCYX 08-07-2025
- Dividend Yield
- UONEK N/A
- SCYX N/A
- EPS Growth
- UONEK N/A
- SCYX N/A
- EPS
- UONEK N/A
- SCYX N/A
- Revenue
- UONEK $437,499,000.00
- SCYX $2,630,000.00
- Revenue This Year
- UONEK N/A
- SCYX $463.61
- Revenue Next Year
- UONEK N/A
- SCYX $310.80
- P/E Ratio
- UONEK N/A
- SCYX N/A
- Revenue Growth
- UONEK N/A
- SCYX N/A
- 52 Week Low
- UONEK $0.44
- SCYX $0.66
- 52 Week High
- UONEK $1.57
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- UONEK 81.13
- SCYX 41.29
- Support Level
- UONEK $0.61
- SCYX $0.70
- Resistance Level
- UONEK $0.71
- SCYX $0.75
- Average True Range (ATR)
- UONEK 0.11
- SCYX 0.05
- MACD
- UONEK 0.04
- SCYX 0.00
- Stochastic Oscillator
- UONEK 81.01
- SCYX 34.29
About UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.